Viatris 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Viatris reported Q3 2026 total revenues of $3.75 billion, adjusted EBITDA of $1.2 billion, and adjusted EPS of $0.71 per share.
- For the first 9 months of the year, total revenues grew 2%, adjusted EBITDA grew 6%, and adjusted EPS grew 8% operationally compared with the prior year.
- Q3 2026 total revenues were in line with expectations; Greater China net sales grew approximately 10% and North America net sales grew approximately 7% versus the prior year.
- North American estradiol patch volumes were approximately double the prior-year period, and products representing over 65% of North American generics net sales were higher-margin complex generics.
- Supply constraints, primarily related to remediation at the Naaschik facility, reduced Q3 revenue by approximately $100 million; the facility received an FDA Official Action Indicated classification in September, and manufacturing was suspended in October.
- Adjusted gross margin was 58%; free cash flow was $814 million, or $895 million excluding transaction and restructuring-related costs and taxes; gross leverage was approximately 2.9 times.
- Viatris returned approximately $717 million of capital to shareholders through the first 3 quarters, including $300 million of share repurchases and the remainder through the quarterly dividend.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please also note today's event is being recorded. At this time, I'd like to turn the floor over to Bill Szablewski, Head of Capital Markets.
Please go ahead. Good morning, everyone.
Welcome to our Q3 2026 earnings call. With us today is our CEO, Scott Smith, Interim CFO, Paul Campbell, Chief R&D Officer, Philippe Martin, and Chief Commercial Officer, Corinne Le Goff. During today's call, we will be making forward-looking statements on a number of matters, including our financial guidance for 2026 and various strategic initiatives. These statements are subject to risk and uncertainties. We will also be referring to certain actual and projected non-GAAP financial measures. Please refer to today's slide presentation and our SEC filings for more information, including reconciliations of those non-GAAP measures to the most directly comparable GAAP measures. When discussing 2026 actual or reported results, we will be making certain comparisons to 2025 actual or reported results on an operational basis, which excludes the impact of foreign currency rates.
When comparing our 2026 actual reported results to our expectations, we are making comparisons to our 2026 financial guidance. With that, I will hand the call over to our CEO, Scott Smith.
Good morning, everyone. We are pleased with our strong third quarter performance, which reflects continued momentum across our businesses. As we have been saying, we believe we have entered a new phase of sustained growth for Viatris. The disciplined execution of the strategy we outlined earlier this year is translating into results. During the third quarter, we delivered total revenues of $3.75 billion, adjusted EBITDA of $1.2 billion, and adjusted EPS of $0.71 per share. Through the first nine months of the year, total revenues grew 2%, adjusted EBITDA grew 6%, and adjusted EPS grew 8% operationally compared to the prior year, demonstrating continued progress towards our long-term financial targets. Given our performance and expectations for continued momentum in the fourth quarter, we are narrowing our financial guidance ranges and once again raising the midpoint for all key financial metrics. Paul will provide more details shortly.
Now let me walk through a few highlights for the quarter. Our base business continues to deliver solid results, reflecting the strength and durability of our portfolio. We are pleased with our performance in North America and Greater China, where we continue to see meaningful growth. In North America, growth is accelerating as our portfolio mix shifts towards more durable, higher-margin products and complex generics, supported by strong demand for our estradiol patches and new product revenue from our recent injectable launches. We are pleased to have launched Gwyn Lo, our low-dose contraceptive patch, in the U.S. in October. In Greater China, growth continues to be driven by strong demand for our cardiovascular portfolio and the strength of our established brands. Regarding our pipeline, we continue to make meaningful progress in advancing our innovative medicines portfolio and positioning the business for long-term growth.
In Japan, we received regulatory approval for WAKIX, which we expect to be an important product launch and a key contributor to the country's strategy to return to growth. In the U.S., we received approval for RYZUMVI for the treatment of presbyopia, and we continue to advance our preparations for the potential approval and launch of fast-acting meloxicam. As a reminder, the PDUFA date for fast-acting meloxicam is December 27, and if approved, we expect to launch early in 2027. In addition, we are approaching the phase III readouts for selatogrel and cenerimod, representing significant milestones for innovative medicines portfolio. Both products have blockbuster potential and could become important growth drivers for us in the next decade. Philippe will provide additional details on these programs and the pipeline shortly.
Finally, I would like to take a moment to discuss our recently announced agreement to acquire Pacira BioSciences and the strategic opportunities we believe this transaction will create for Viatris. I am excited about the potential of the Pacira business. I believe this acquisition represents a significant step forward for Viatris and is a strong example of the business development strategy we are executing to support our long-term growth. More specifically, the transaction would add two established patent-protected medicines in the U.S., EXPAREL and ZILRETTA, further strengthening our U.S. promoted brands business with durable revenue and margins well above our company average. With the addition of Pacira's products, we expect our U.S. innovative medicines business to generate more than $1 billion in total revenue in 2027. We are also exploring potential opportunities to leverage our global infrastructure to develop and commercialize Pacira's products in selected markets outside of the U.S.
Additionally, Pacira would bring an experienced U.S. team and established capabilities across sales, marketing, market access, medical affairs, and global R&D that complement our existing infrastructure. We believe these capabilities could help us maximize the potential of fast-acting meloxicam and position Viatris to become a leader in non-opioid pain management. Before I turn it over to Philippe, I want to recognize a recent leadership transition. After more than 30 years with Viatris and our legacy companies, Peter McCormick retired as our Chief Supply Officer on November 1. I want to personally thank Peter for his tremendous contribution and years of dedicated leadership. With Peter's transition, I am very pleased to welcome Paul Duffy as our new Chief Supply Officer. Paul brings 35 years of industry experience across global supply chain management, manufacturing, strategy, and business transformation. I am looking forward to working very closely with him.
With that, I'll turn it over to Philippe.
Philippe? Thank you, Scott. We continue to execute with discipline across our pipeline and remain on track to deliver against our R&D priorities.
Starting with our value-added medicines, the FDA review of our fast-acting meloxicam NDA is substantially complete, with FDA being very engaged with us throughout the review process. We are on track to start labeling negotiations this month ahead of an anticipated regulatory decision by our PDUFA goal date of December 27. We continue to view fast-acting meloxicam as a potentially meaningful addition to the acute pain treatment landscape, given its rapid absorption profile, clinically meaningful pain relief, and demonstrated reduction in opioid use. Over the past two years, we've been working on bringing additional benefits to patients through lifecycle management opportunities, including label expansions or additional indications. To this end, we recently secured on-time approval for the presbyopia indication for RYZUMVI in the U.S.
We also submitted a Type II Variation application in Europe for Creon to expand its approved dosing range for non-cystic fibrosis indications, which represents a significant opportunity to expand the value of these important products for patients. We anticipate a regulatory decision in the first half of 2027. Regarding our women's health portfolio, we continue to leverage our transdermal capabilities to address important unmet needs. We have received approval and launched Gwyn Lo in the U.S. We continue to advance our next patch candidate, a norethindrone-only weekly patch, for which we have completed phase III enrollment and anticipate a data readout in the first half of 2027. In Japan, our Nefecon program for patients with IgA nephropathy continue to advance as planned, following the positive phase III results announced earlier this year.
We remain on track to submit our JNDA by the end of this year, with a regulatory decision anticipated in the second half of 2027. Turning to our innovative pipeline, cenerimod continues to progress well, with both phase III SLE studies, OPUS 1 and OPUS 2, advancing as planned. We remain on track to report results in the first half of 2027. In addition, the phase III LUMIOS study in lupus nephritis is actively enrolling patients. For selatogrel, enrollment in our SOS-AMI phase III studies continues to track well. We continue to expect a data readout around the first half of 2027, keeping in mind the event-driven design of the study. Turning to our generic pipeline, where our execution remains strong. We are on track to secure over 100 new product approvals this year, reflecting the strength and breadth of our development and regulatory capabilities.
Importantly, we are preparing to launch our once-monthly aripiprazole injection in the U.S., for which we were the first to secure final FDA approval. In addition, we have secured first-to-file status for WEGOVY, or semaglutide 25 milligram tablets, further strengthening our pipeline of generic GLP-1s. Lastly, with the announced acquisition of Pacira, we see an opportunity to bolster our global R&D platform with new talent, capabilities, and programs. There are several pipeline programs of interest for which there are upcoming readouts, including the phase II part A readout for the osteoarthritis gene therapy asset PCRX-201. We will make sure to keep you updated on the status of this program following deal close. Overall, we expect a strong finish to the year and believe we are well-positioned heading into 2027, with several important regulatory and clinical milestones across our innovative, value-added, and generic pipeline.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
15 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
